- Fee assured
- Verified this account
This healthcare professional let us know that they are currently available for:
- Face-to-face consultations
- Phone consultations
- Video consultations
Last updated: 12 Nov 2020
Dr Jonathan Sive is a Consultant Haematologist and the Clinical Service Lead for Myeloma at University College London Hospital (UCLH). He is highly experienced in the diagnosis and management of blood cancers, particularly in myeloma and other plasma cell disorders such as MGUS and plasmacytomas. He also has expertise in the investigation of anaemia and other abnormal blood counts.
He is an active member of the UK Myeloma Research Alliance where he is involved in the planning and management of national clinical trials. He is also an executive member of the UK Myeloma Forum where he coordinates myeloma management and guidelines at a national level. He is the chair of the UK national guidelines group for the initial treatment of myeloma.
Dr Sive completed his specialist haematology training at UCLH and carried out a PhD in Molecular Haematology at Cambridge University, for which he was awarded a Cancer Research UK Clinical Fellowship. He remains actively engaged in a variety of clinical research projects and his work has been widely published in peer-reviewed journals and textbooks.
Dr Sive is dedicated to improving outcomes and wellbeing for his patients, and combines professional, expert advice with a caring and sympathetic manner. He is registered as a provider with all major UK insurance companies and is also happy to see uninsured self -pay patients.
Areas of interest
Haematological malignancy; myeloma; MGUS; general haematology (including investigation and management of paraproteins, anaemia, high and low white cell counts, neutropenia, high and low platelet counts, iron deficiency)
Current NHS consultant posts held
University College London Hospital
Novel treatments and clinical trials for myeloma
Academic Clinical Fellowship for Haematology specialist training
Cancer Research UK Clinical Research Fellowship for PhD at Cambridge University
American Society of Hematology Abstract Achievement Award
High rates of venous and arterial thrombotic events in patients with POEMS syndrome: results from the UCLH (UK) POEMS Registry.Sayar Z, Weatherill A, Keddie S, Sive J, Lunn MP, Thomas M, D'Sa S.Blood Adv. 2020 May 26;4(10):2139-2142
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.Chavda SJ, Pocock R, Cheesman S, Lee KM, Dowling E, Marks DJB, Kyriakou C, Lee L, Sive J, Wechalekar A, Rabin N, Yong K, Popat R. Br J Haematol. 2020 Jun 14.
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Chin M, Sive JI, Allen C, Roddie C, Chavda SJ, Smith D, Blombery P, Jones K, Ryland GL, Popat R, Rismani A, D'Sa S, Rabin N, Gale RE, Yong KL. Blood Cancer J. 2017 Sep 15;7(9):
Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia. Sive JI, Basilico S, Hannah R, Kinston SJ, Calero-Nieto FJ, Göttgens B. Leukemia. 2016 Jan;30(1):14-23.
Global hypomethylation in myeloma is associated with poor prognosis. Sive JI, Feber A, Smith D, Quinn J, Beck S, Yong K. Br J Haematol. 2016 Feb;172(3):473-5.
Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia. Oram SH, Thoms J, Sive JI, Calero-Nieto FJ, Kinston SJ, Schütte J, Knezevic K, Lock RB, Pimanda JE, Göttgens B. Leukemia. 2013 Jun;27(6):1348-57.
Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Sive JI, Thomson KJ, Morris EC, Ward KN, Peggs KS.
Clin Infect Dis. 2012 Nov 15;55(10):1362-70.
Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience. Sive J, Ardeshna KM, Cheesman S, le Grange F, Morris S, Nicholas C, Peggs K, Statham P, Goldstone AH. Leuk Lymphoma. 2012 Dec;53(12):2397-404.
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, Marks DI, McMillan A, Moorman AV, Richards SM, Rowe JM, Tallman MS, Goldstone AH. Br J Haematol. 2012 May;157(4):463-71.
Haematological Cancer. Sive JI and Foggo V in Kumar and Clark's Clinical Medicine (10th Edition). Elsevier, London 2020.
Courses offered to GPs
Common haematology referrals
Introduction to myeloma
- MBChB University of Manchester 2002
- MRCP Royal College of Physicians 2005
- PhD University of Cambridge 2016
- FRCPath Royal College of Pathologists 2013
Reference number 6054442
Professional bodies (positions held - last 3 yrs)
- Consultant Haematologist University College London Hospital 2019
Affiliations / memberships
British Society for Haematology
UK Myeloma Forum
UK Myeloma Research Alliance
- University College Hospital235 Euston...
- 08:00 - 13:00
- 020 3447 1719
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.